Shanghai Pharmaceuticals (Germany) Performance
| S1R Stock | EUR 1.58 0.01 0.63% |
On a scale of 0 to 100, Shanghai Pharmaceuticals holds a performance score of 13. The entity has a beta of 0.94, which indicates possible diversification benefits within a given portfolio. Shanghai Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Shanghai Pharmaceuticals is expected to follow. Please check Shanghai Pharmaceuticals' downside deviation, total risk alpha, value at risk, as well as the relationship between the information ratio and treynor ratio , to make a quick decision on whether Shanghai Pharmaceuticals' existing price patterns will revert.
Risk-Adjusted Performance
13 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Shanghai Pharmaceuticals Holding are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Shanghai Pharmaceuticals reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 19.6 B | |
| Total Cashflows From Investing Activities | -6 B | |
| Free Cash Flow | 942.6 M |
Shanghai |
Shanghai Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 114.00 in Shanghai Pharmaceuticals Holding on September 23, 2024 and sell it today you would earn a total of 44.00 from holding Shanghai Pharmaceuticals Holding or generate 38.6% return on investment over 90 days. Shanghai Pharmaceuticals Holding is currently producing 0.5495% returns and takes up 3.3094% volatility of returns over 90 trading days. Put another way, 29% of traded stocks are less volatile than Shanghai, and 90% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Shanghai Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Shanghai Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Shanghai Pharmaceuticals Holding, and traders can use it to determine the average amount a Shanghai Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.166
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | S1R | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.31 actual daily | 29 71% of assets are more volatile |
Expected Return
| 0.55 actual daily | 10 90% of assets have higher returns |
Risk-Adjusted Return
| 0.17 actual daily | 13 87% of assets perform better |
Based on monthly moving average Shanghai Pharmaceuticals is performing at about 13% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Shanghai Pharmaceuticals by adding it to a well-diversified portfolio.
Shanghai Pharmaceuticals Fundamentals Growth
Shanghai Stock prices reflect investors' perceptions of the future prospects and financial health of Shanghai Pharmaceuticals, and Shanghai Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Shanghai Stock performance.
| Return On Equity | 0.1 | |||
| Return On Asset | 0.0281 | |||
| Profit Margin | 0.02 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 8.94 B | |||
| Shares Outstanding | 919.07 M | |||
| Price To Earning | 6.59 X | |||
| Price To Book | 0.67 X | |||
| Price To Sales | 0.04 X | |||
| Revenue | 215.82 B | |||
| EBITDA | 10.73 B | |||
| Cash And Equivalents | 23.68 B | |||
| Cash Per Share | 8.33 X | |||
| Total Debt | 7.16 B | |||
| Debt To Equity | 0.67 % | |||
| Book Value Per Share | 17.90 X | |||
| Cash Flow From Operations | 5.06 B | |||
| Earnings Per Share | 0.23 X | |||
| Total Asset | 163.44 B | |||
About Shanghai Pharmaceuticals Performance
By analyzing Shanghai Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Shanghai Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Shanghai Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Shanghai Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Shanghai Pharmaceuticals Holding Co., Ltd., an investment holding company, researches, develops, manufactures, distributes, and retails pharmaceutical and healthcare products in the Peoples Republic of China. Shanghai Pharmaceuticals Holding Co., Ltd. is a subsidiary of Shanghai Pharmaceutical Co., Ltd. SHANGHAI PHARM operates under Medical Distribution classification in Germany and is traded on Frankfurt Stock Exchange. It employs 46609 people.Things to note about Shanghai Pharmaceuticals performance evaluation
Checking the ongoing alerts about Shanghai Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Shanghai Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Shanghai Pharmaceuticals may become a speculative penny stock | |
| Shanghai Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| About 22.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Shanghai Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Shanghai Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Shanghai Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Shanghai Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Shanghai Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Shanghai Pharmaceuticals' stock. These opinions can provide insight into Shanghai Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Shanghai Stock analysis
When running Shanghai Pharmaceuticals' price analysis, check to measure Shanghai Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Shanghai Pharmaceuticals is operating at the current time. Most of Shanghai Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Shanghai Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Shanghai Pharmaceuticals' price. Additionally, you may evaluate how the addition of Shanghai Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |